The drug is already on the market in the US for the treatment of heart failure under the brand name Inpefa. Lexicon is also studying the drug for the treatment of hypertrophic cardiomyopathy.

According to Lexicon, Inpefa (sotagliflozin) will continue to be manufactured and made available to patients. The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL ...

Lexicon Pharmaceuticals drug Inpefa is now FDA-approved for heart failure. Inpefa is third in its class, but the biotech says its pill can reach a specific subset of patients, enabling it to stand ...